Abstracts tagged "prognostic factors"

Abstract Number: 2450 • ACR Convergence 2024
Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients
Eva Hoekstra¹, S. Ahmed², David Ueckert³, Nina Ajmone Marsan³, Philippine Kiès³, M.K. Ninaber³, Marlies Heuvers³, Miranda Geelhoed³, Thomas Huizinga⁴ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Leids Universitair Medisch Centrum, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Disease progression in systemic sclerosis (SSc) is characterized by severe and early progression in anti-topoisomerase (ATA) positive diffuse cutaneous patients and typically involves lung…
Abstract Number: 0574 • ACR Convergence 2024
14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study
Anthony Marotta¹, Walter Maksymowych², Stephanie Wichuk² and Navneet Sidhu¹, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Diagnosis of axial spondyloarthritis (AxSpA) is challenging and often delayed primarily due to the lack of sensitive and specific markers needed for accurate and…
Abstract Number: 1590 • ACR Convergence 2024
Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Emily Langballe², Hilde Jenssen Bjørkekjær³, Henriette Didriksen¹, Phuong Phuong Diep⁴, Anna Helena Andersson¹, Ragnar Gunnarsson¹, Michael T Durheim¹, Torhild Garen¹, Øyvind Midtvedt⁵, Trond Mogens Aaløkken⁶, Øyvind Molberg⁷ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, ⁴Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, ⁵Oslo University Hospital, Oslo, Oslo, Norway, ⁶Medicine, Oslo, Norway, Oslo, Norway, ⁷Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). While impaired lung function with forced vital capacity (FVC) <…
Abstract Number: 2451 • ACR Convergence 2024
Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients
Chiara Bellocchi¹, Alessandro Santaniello², Silvia Bosello³, Enrico De Lorenzis⁴, Gerlando Natalello⁵, Nicoletta Del Papa⁶, Silvia Cavalli⁷, Devis Benfaremo⁸, Giacomo De Luca⁹, Corrado Campochiaro¹⁰, Lorenzo Cavagna¹¹, Veronica Codullo¹², Francesco Bonomi¹³, gaia Montanelli¹⁴, Adriana Severino¹⁵, Monica Caronni², Martina Iacubino¹⁶, Barbara Vigone², Silvia Bellando-Randone¹⁷, Carlomaurizio Montecucco¹⁸, Marco Matucci-Cerinic¹⁹, Lorenzo Dagna²⁰, Gianluca Moroncini⁸, Roberto Caporali²¹ and Lorenzo Beretta²², ¹Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, MILANO, Italy, ³FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI- IRCCS, Rome, Rome, Italy, ⁴Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁶ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Milan, Italy, ⁷University of Milan, Milan, Milan, Italy, ⁸Marche Polytechnic University, Ancona, Italy, ⁹Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁰IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹¹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ¹²Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ¹³Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Milan, Italy, ¹⁶Università degli Studi di Milano, Milano, Italy, ¹⁷University of Florence, Florence, Florence, Italy, ¹⁸IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ¹⁹University San Raffaele Milano, Milano, Milan, Italy, ²⁰Ospedale San Raffaele, Milano, Italy, ²¹Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc). Pulmonary function tests (PFTs) can serve as useful surrogate measures…
Abstract Number: 0644 • ACR Convergence 2023
Prediction of Stable SSc-ILD Depends on Definition of ILD Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Carina Mihai⁶, Oyvind Midtvedt¹, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
Abstract Number: 1301 • ACR Convergence 2023
The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis
Maryam Adas¹, Sam Norton¹, Andrew Cope¹, Maya Buch², James Galloway¹ and Elena Nikiphorou¹, ¹King's College London, London, United Kingdom, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Psychosocial factors may interplay with biological factors to drive a refractory disease state in patients with inflammatory arthritis1. We aim to explore which socioeconomic,…
Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Dafna Gladman², Murray Urowitz³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
Abstract Number: 0645 • ACR Convergence 2023
Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Oyvind Midtvedt¹, Carina Mihai⁶, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: We have previously shown that short term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) is associated with mortality. However, it is…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 2301 • ACR Convergence 2023
Relapse in Japanese Patients with Newly Diagnosed SLE and Its Clinical Characteristics in Daily Clinical Practice: A Single Center Experience in Recent 10 Years
Shuzo Sato¹, Shuhei Yoshida¹, Yuya Sumichika¹, Kenji Saito¹, Haruki Matsumoto¹, Jumpei Temmoku¹, Yuya Fujita¹, Naoki Matsuoka¹, Tomoyuki Asano¹ and KIYOSHI MIGITA², ¹Fukushima Medical University, Fukushima, Japan, ²Department of Rheumatology Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: SLE patients often experience relapse in the course of treatment, in spite of the progress of therapeutic strategy in SLE. The purpose of this…
Abstract Number: 0124 • ACR Convergence 2023
Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa-Parra¹, Andrew Hanson², Alain Sanchez-Rodriguez³, Jose Meade-Aguilar¹, Cynthia Crowson³ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Patients with SLE experience increased all-cause mortality and have a higher risk of hospitalization than the general population. Recently the classification criteria for SLE…
Abstract Number: 0656 • ACR Convergence 2023
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
enrico De Lorenzis¹, Francesco Del Galdo², gerlando Natalello¹, Stefano Di Donato², lucrezia verardi¹, Vishal Kakkar², pier giacomo Cerasuolo¹, Francesco Varone³, Luca Richeldi³, Maria Antonietta D'Agostino¹ and Silvia Bosello¹, ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³Division of Pulmonology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in systemic sclerosis (SSc) is a common complication that has varied progression rate and prognosis. Different progression definitions include minimal…
Abstract Number: 1390 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…
Abstract Number: 2309 • ACR Convergence 2023
Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus
Luis Vega Sevilla¹, Oscar E. Alvarez-González², Janett Riega-Torres³, Cassandra Michele Skinner-Taylor³, Diana Carolina Rubio Torres⁴, Lucio Vera Cabrera⁵, Dionicio A. Galarza-Delgado⁶, Jesus Alberto Cardenas-De la Garza⁷, Rodrigo J. Castillo-de la Garza⁵, Mario Alberto Aguilera Valenciano⁵, wendy Escalante⁵ and Hector Guerra⁸, ¹Hospital Universitario UANL, Garcia, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Faculty of Medicine and University Hospital Dr. José Eleuterio González, UANL, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico, ⁷Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁸Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with epithelial defects and disrupted intestinal barrier, risking bacterial translocation, and promoting systemic inflammation, known as dysbiosis, which…
Abstract Number: 0127 • ACR Convergence 2023
Time Trends, Cumulative Incidence, and Impact on Survival of Interstitial Lung Disease in Systemic Sclerosis: Results from a Population-based Cohort Study
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Cardiopulmonary complications are the number one cause of mortality in Systemic sclerosis (SSc). We studied the prevalence, cumulative incidence, predictors and impact of interstitial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.